Lipocine's Oral Brexanolone Shows Promising CNS Activity for Neuropsychiatric Disorders

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company specializing in enhancing therapeutics through its proprietary oral delivery technology, has announced positive results from a qEEG study of its oral brexanolone. Brexanolone is a bioidentical neuroactive steroid (NAS) being developed for treating postpartum depression (PPD). The study revealed robust CNS activity, with concentration- and time-dependent post-dose changes in qEEG, confirming GABAA positive allosteric modulation. These findings support the potential use of oral brexanolone in treating various neuropsychiatric conditions.

Dr. Mahesh Patel, President and CEO of Lipocine, expressed optimism about the results, stating, "The qEEG findings confirm target engagement of oral brexanolone, suggesting it could be useful for treating a range of psychiatric conditions such as depression and anxiety, and neurological disorders like essential tremor and epilepsy."

The Phase 1 study involved 12 healthy postmenopausal women who received single doses of oral brexanolone. EEG recordings and blood samples were collected before and after dosing. The spectral analysis revealed changes in brain wave activity, particularly in the theta, alpha1, and beta bands. Most changes were observed as early as two hours post-dose, peaking at four hours and lasting up to 12 hours. These findings, along with the drug's favorable safety profile, support further development of oral brexanolone.